Pertuzumab: Uses, Dosage, Side Effects & Brands | MedexInfo
Pertuzumab
Rx Only
Generic NamePertuzumab
Therapeutic ClassMonoclonal Antibody (HER2 Inhibitor)
Common Dose840 mg loading → 420 mg q3 weeks
Max / 24hAs per protocol
PregnancyCategory D
Indications ▼
HER2-positive metastatic breast cancer (in combination with trastuzumab and docetaxel)
Neoadjuvant treatment of HER2-positive early breast cancer
Adjuvant therapy in high-risk HER2-positive breast cancer
Mechanism & Pharmacokinetics ▼
Mechanism: Binds to extracellular dimerization domain (subdomain II) of HER2 receptor, preventing HER2 heterodimerization and downstream signaling. Enhances antibody-dependent cellular cytotoxicity (ADCC).
Pharmacokinetics: Administered IV. Terminal half-life approximately 18 days. Steady-state achieved after ~3 cycles. Clearance not significantly affected by mild renal impairment.
Dosage & Administration ▼
| Patient Category | Recommended Dose | Max / 24h |
|---|---|---|
| Adults (Loading Dose) | 840 mg IV over 60 minutes | 840 mg |
| Adults (Maintenance) | 420 mg IV every 3 weeks over 30–60 minutes | 420 mg |
| Elderly | No dose adjustment required | As per protocol |
Note: Administer before trastuzumab when given sequentially. Monitor cardiac function (LVEF) before and during therapy.
Side Effects ▼
Common: Diarrhea, alopecia, neutropenia, fatigue, nausea
Occasional: Infusion-related reactions, rash, mucositis
Serious: Left ventricular dysfunction, febrile neutropenia, hypersensitivity reactions
Contraindications ▼
Hypersensitivity to pertuzumab or formulation components
Severe uncontrolled cardiac disease
Drug Interaction ▼
Trastuzumab: used in combination therapy
Chemotherapy agents (docetaxel): monitor toxicity
Avoid concurrent cardiotoxic drugs if possible
Pregnancy & Lactation ▼
Category D – may cause fetal harm
Effective contraception required during treatment and for 7 months after last dose
Breastfeeding not recommended during therapy
Clinical / Research Summary ▼
Clinical trials (CLEOPATRA study) demonstrated improved progression-free and overall survival when added to trastuzumab and docetaxel.
Dual HER2 blockade significantly enhances tumor response in early and metastatic breast cancer.
Cardiac monitoring is essential due to risk of reduced LVEF.
Patient Counseling Points ▼
Report shortness of breath, swelling, or palpitations immediately.
Expect possible diarrhea and hair loss.
Use effective contraception during and after treatment.
Storage & Handling ▼
Store refrigerated at 2–8°C
Do not freeze or shake
Protect from light
Brand Names (Bangladesh & Global) ▼
Bangladesh:
Global:
Perjeta® 420 mg/14 ml
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult a qualified healthcare provider.
.png)
